Cortexa Builds MDMA Supply Leadership as Australian Psychedelic Market Expands

Cronos Australia Ltd. ( (AU:VIT) ) has issued an announcement.

Melbourne-based Cortexa, a 50/50 joint venture between Vitura Health and PharmAla Biotech, is a leading Australian supplier of psychedelic medicines focused on MDMA for regulated clinical use. Its products support local clinical research and patient treatments under the Therapeutic Goods Administration’s Authorised Prescriber Scheme, following the 2023 opening of prescribing pathways for psychedelics in specific mental health conditions.

Cortexa has sold most of its first Australian GMP batch of MDMA capsules, with forecast sales from that batch expected to exceed AUD$1 million, and has secured national supply arrangements with authorised providers. PharmAla has begun producing a second GMP batch featuring a new 20mg dosage form due in the second quarter of 2026, while the expiry of a three-year licence fee arrangement will reduce costs but preserve exclusive manufacturing and IP access, supporting Vitura’s revenue diversification and Cortexa’s growth as reimbursement and support programs for psychedelic therapies expand.

The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.04 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.

More about Cronos Australia Ltd.

Vitura Health Limited is an ASX-listed diversified digital health company that operates the Canview online ecosystem through its subsidiary Burleigh Heads Cannabis. Canview links prescribers, patients, pharmacies and suppliers, distributing about 600 therapeutic product and device SKUs from around 70 brands to roughly 4,700 Australian pharmacies.

Average Trading Volume: 316,121

Technical Sentiment Signal: Sell

Current Market Cap: A$25.18M

Learn more about VIT stock on TipRanks’ Stock Analysis page.